Tetanus is a fatal disease that is widespread in underdeveloped countries. Tetanus occurs after injuries, which are the entry point for infection with Clostridium tetani. The bacillus itself secretes a strong and potent exotoxin that causes intoxication of the body, which can be manifested by neuromuscular dysfunction. Tetanospasmin, as a powerful neurotoxin, can lead to a fatal outcome of this disease if adequate protection is not prescribed in time after the injury to prevent further intoxication with this exotoxin. Even greater importance should be attached to neonatal tetanus, which has been more common in rural areas over the last century. The vaccine is one of the safest and most effective measures in the fight against tetanus, as it provides long-term protection in fully immunized individuals. Surgical treatment, appropriate wound care, and the administration of anti-tetanus serum and the vaccine in the first hours after the injury lead to 100% protection against this deadly disease. Objective. To determine whether regular vaccination against tetanus in children in the Šumadija District has been successfully carried out over five years from 2018 to 2022 to achieve satisfactory immunity and protection against this disease for a certain period. Results and discussion. The lowest success rate in immunization against tetanus for the observed five-year period was observed in 2020: 72% for the booster vaccination at the age of seven and 86% for the booster vaccination at the age of fourteen for the area of Šumadija District. Even during the current COVID-19 pandemic in the calendar year 2021, a low tetanus vaccination coverage rate is observed compared to before the pandemic. Based on statistically processed and summarized data, it can be said that the vaccination coverage rate for 2021 is significantly lower for the first vaccination in the first year of life and is 89%, the booster vaccination in the second year of life is 90% and in the fourteenth year of life 87%. It is important to pay attention to immunization status and the completeness and regularity of tetanus vaccination. In some developed countries, special attention is paid to the assessment of tetanus vaccination status by reviewing medical records as part of primary health care. Conclusion. Continuous and improved education of physicians (especially surgeons, anesthesiologists, and emergency physicians) about immunization of the childhood population according to the calendar of mandatory vaccinations against tetanus in the form of panel discussions, lectures, and professional conferences is extremely important. Immunoprophylaxis in children and immunoprophylaxis together with seroprophylaxis and chemoprophylaxis in the elderly is the key to success in the fight against tetanus.

1. P. Poudel, S. Budhathoki, S. Manandhar, “Tetanus,” Kathmandu Univ. Med. J., vol. 7, no. 27, pp. 315 – 322, Jul.-Sep. 2009.
   PMid: 20071883
2. A. Chrdle, M. Balejová, “Tetanus Still Current,” Acta Chir. Orthop. Traumatol. Cech., vol. 87, no. 4, pp. 292 – 296, 2020.
   DOI: 10.55095/achot2020/044
   PMid: 32940226
3. A. Megighian, M. Pirazzini, F. Fabris, O. Rossetto, C. Montecucco, “Tetanus and tetanus neurotoxin: From peripheral uptake to central nervous tissue targets,” J. Neurochem., vol. 158, no. 6, pp. 1244 – 1253, Sep. 2021.
   DOI: 10.1111/jnc.15330
   PMid: 33629408
4. J. R. Hardin, J. D. Sobel, N. M. Franklin, N. A. Friedman, A. A. Kreshak, “Generalized Tetanus with Opisthotonos,” J. Emerg. Med., vol. 64, no. 6, pp. 724 – 725, Jun. 2023.
   DOI: 10.1016/j.jemermed.2023.03.057
   PMid: 37286437
5. D. Chapeton-Montes et al., “Tetanus Toxin Synthesis is Under the Control of A Complex Network of Regulatory Genes in Clostridium tetani,” Toxins, vol. 12, no. 5, 328, May 2020.
   DOI: 10.3390/toxins12050328
   PMid: 32429286
   PMCid: PMC7290440
6. A. S. Tartar, A. Akbulut, İ. Demirel, “Tetanus: A disease not to be forgotten,” Rev. Soc. Bras. Med. Trop., vol. 56, e0586, Mar. 2023.
   DOI: 10.1590/0037-8682-0586-2022
   PMid: 36888785
   PMCid: PMC9991102
7. I. Stock, “Tetanus and Clostridium tetani–a brief review,” Med. Monatsschr. Pharm., vol. 38, no. 2, pp. 57 – 60, Feb. 2015.
   PMid: 26376540
8. H. Imtiaz, H. Hakeem, A. Alam, D. Kanwar, “Making an objective diagnosis of tetanus—utility of a simple neurophysiological test,” BMJ Case Rep., vol. 12, no. 12, e232344, Dec. 2019.
   DOI: 10.1136/bcr-2019-232344
   PMid: 31796435
   PMCid: PMC7001727
9. T. Martín-Casquero, E. Ruescas-Escolano, J. Tuells, “Use of the tetanus quick stick (TQS) test in the emergency services,” Med. Clin., vol. 153, no. 10, pp. 394 – 401, Nov. 2019.
   DOI: 10.1016/j.medcli.2019.06.004
   PMid: 31445749
10. K. Y. Niu, Y. K. Lin, “Generalized tetanus,” CMAJ, vol. 191, no. 34, E944, Aug. 2019.
    DOI: 10.1503/cmaj.190161
    PMid: 31451526
    PMCid: PMC6710078
11. L. M. Yen, C. L. Thwaites, “Tetanus,” Lancet, vol. 393, no. 10181, pp. 1657 – 1668, Apr. 2019.
    DOI: 10.1016/S0140-6736(18)33131-3
    PMid: 30935736
12. P. Finkelstein, L. Teisch, C. J. Allen, G. Ruiz, “Tetanus: A Potential Public Health Threat in Times of Disaster,” Prehosp. Disaster Med., vol. 32, no. 3, pp. 339 – 342, Jun. 2017.
    DOI: 10.1017/S1049023X17000012
    PMid: 28215195
13. C. L. Thwaites, H. T. Loan, “Eradication of tetanus,” Br. Med. Bull., vol. 116, no. 1, pp. 69 – 77, Dec. 2015.
    DOI: 10.1093/bmb/ldv044
    PMid: 26598719
    PMCid: PMC4674006
14. J. L. Liang et al., “Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP),” Morb. Mortal. Wkly. Rep., vol. 67, no. 2, pp. 1 – 44, Apr. 2018.
    DOI: 10.15585/mmwr.rr6702a1
    PMid: 29702631
    PMCid: PMC5919600
15. B. Pfausler, V. Rass, R. Helbok, R. Beer, “Toxin-associated infectious diseases: tetanus, botulism and diphtheria,” Curr. Opin. Neurol., vol. 34, no. 3, pp. 432 – 438, Jun. 2021.
    DOI: 10.1097/WCO.0000000000000933
    PMid: 33840775
16. I. Condé et al., “Neonatal and postneonatal tetanus at a referral hospital in Kamsar, Guinea: a retrospective audit of pediatric records (2014-2018),” Int. Health, vol. 14, no. 5, pp. 468 – 474, Sep. 2022.
    DOI: 10.1093/inthealth/ihab021
    PMid: 34048561
    PMCid: PMC9450648
17. M. Z. Vouking, C. N. Tadenfok, J. M. E. Ekani, “Strategies to increase immunization coverage of tetanus vaccine among women in Sub Saharan Africa: a systematic review,” Pan Afr. Med. J., vol. 27, suppl. 3, 25, Jun. 2017.
    DOI: 10.11604/pamj.supp.2017.27.3.11535
    PMid: 29296160
    PMCid: PMC5745987
18. C. L. Thwaites et al., “Seroprotection against tetanus in southern Vietnam,” Vaccine, vol. 41, no. 13, pp. 2208 – 2213, Mar. 2023.
    DOI: 10.1016/j.vaccine.2023.02.036
    PMid: 36849339
    PMCid: PMC10580288
19. T. Rabadi, M. F. Brady, “Tetanus Toxoid,” in StatPearls [Internet], Treasure Island (FL), USA: StatPearls Publishing, Jan. 2024.
    PMid: 32491347
20. J. S. Sheffield, S. M. Ramin, “Tetanus in pregnancy,” Am. J. Perinatol., vol. 21, no. 4, pp. 173 – 182, May 2004.
    DOI: 10.1055/s-2004-828605
    PMid: 15168315
21. A. H. Nassar, E. Hobeika, D. Chamsy, F. El-Kak, I. M. Usta, “Vaccination in pregnancy,” Int. J. Gynaecol. Obstet., vol. 162, no. 1, pp. 18 – 23, Jul. 2023.
    DOI: 10.1002/ijgo.14876
    PMid: 37283471
22. M. Prygiel, E. Mosiej, P. Górska, A. A. Zasada, “Diphtheria-tetanus-pertussis vaccine: past, current & future,” Future Microbiol., vol. 17, no. 3, pp. 185 – 197, Feb. 2022.
    DOI: 10.2217/fmb-2021-0167
    PMid: 34856810
23. K. Yang, H. Kim, E. Ortiz, C. Huoi, J. Kang, “Post-Marketing Safety Surveillance of a Childhood Pentavalent Diphtheria-Tetanus-Acellular Pertussis-Polio and Haemophilus influenzae Type B (DTaP-IPV/Hib) Vaccine in South Korea,” Infect. Dis. Ther., vol. 12, no. 2, pp. 499 – 511, Feb. 2023.
    DOI: 10.1007/s40121-022-00724-7
    PMid: 36520326
    PMCid: PMC9925623
24. C. Huoi, J. Vargas-Zambrano, D. Macina, E. Vidor, “A combined DTaP-IPV vaccine (Tetraxim®/Tetravac®) used as school-entry booster: a review of more than 20 years of clinical and post-marketing experience,” Expert Rev. Vaccines, vol. 21, no. 9, pp. 1215 – 1231, Sep. 2022.
    DOI: 10.1080/14760584.2022.2084076
    PMid: 35983656
25. F. Bagordo et al., “Seroprotection against tetanus in the Italian general population,” Vaccine, vol. 42, no. 19, pp. 4040 – 4045, Jul. 2024.
    DOI: 10.1016/j.vaccine.2024.05.015
    PMid: 38762356
26. E. Stănică et al., “Effectiveness of booster immunization using small doses of diphtheria-tetanus bivaccine in adults,” Arch. Roum. Pathol. Exp. Microbiol., vol. 33, no. 1, pp. 5 – 16, Mar. 1974.
    PMid: 4827810
27. M. Ulfa, N. A. Husna, “A case report of generalized tetanus in a 42-year-old man with dental infection,” J. Basic Clin. Physiol. Pharmacol., vol. 30, no. 6, Dec. 2019.
    DOI: 10.1515/jbcpp-2019-0243
    PMid: 31811803
28. P. Finkelstein, L. Teisch, C. J. Allen, G. Ruiz, “Tetanus: A Potential Public Health Threat in Times of Disaster,” Prehosp. Disaster Med., vol. 32, no. 3, pp. 339 – 342, Jun. 2017.
    DOI: 10.1017/S1049023X17000012
    PMid: 28215195
29. Izveštaji o sprovedenoj imunizaciji na teritoriji Republike Srbije u 2018, 2019, 2020, 2021 i 2022. godini, Institut za javno zdravlje Srbije “Dr Milan Jovanović Batut”, Beograd, Srbija, 2023.
    (Reports on immunization carried out on the territory of the Republic of Serbia in 2018, 2019, 2020, 2021 and 2022, Institute for Public Health of Serbia “Dr Milan Jovanović Batut”, Belgrade, Serbia, 2023.)
    Retrieved from: https://www.batut.org.rs/index.php?category%20id=140
    Retrieved on: Jan. 5, 2024
30. Y. Lamberto et al., “Tetanus: an immunopreventable disease,” Medicina, vol. 83, no. 5, pp. 841 – 845, 2023.
    PMid: 37870348
31. K. Habas et al., “Resolution of coronavirus disease 2019 (COVID-19),” Expert Rev. Anti Infect. Ther., vol. 18, no. 12, pp. 1201 – 1211, Dec. 2020.
    DOI: 10.1080/14787210.2020.1797487
    PMid: 32749914
32. R. Ochani et al., “COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management,” Infez Med., vol. 29, no. 1, pp. 20 – 36, Mar. 2021.
    PMid: 33664170
33. M. Maniruzzaman et al., “COVID-19 diagnostic methods in developing countries,” Environ. Sci. Pollut. Res. Int., vol. 29, no. 34, pp. 51384 – 51397, Jul. 2022.
    DOI: 10.1007/s11356-022-21041-z
    PMid: 35619009
    PMCid: PMC9135468
34. M. Li et al., “COVID-19 vaccine development: milestones, lessons and prospects,” Signal Transduct. Target. Ther., vol. 7, no. 1, 146, May 2022.
    DOI: 10.1038/s41392-022-00996-y
    PMid: 35504917
    PMCid: PMC9062866